Research programme: gene therapies - Adverum Biotechnologies

Drug Profile

Research programme: gene therapies - Adverum Biotechnologies

Alternative Names: AAV.7m8-aflibercept; AAV.7m8-ranibizumab; ADVM-022; ADVM-032; ANN-003; ANN-004

Latest Information Update: 20 Oct 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Weill Cornell Medical College
  • Developer Adverum Biotechnologies; Weill Cornell Medical College
  • Class Antiallergics; Eye disorder therapies; Gene therapies; Heart failure therapies; Hepatoprotectants
  • Mechanism of Action Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Hypersensitivity; Wet age-related macular degeneration
  • Research Cardiomyopathies

Most Recent Events

  • 08 Nov 2017 Adverum Biotechnologies plans to file an IND application of ADVM 022 with the US FDA in USA for Wet age-related macular degeneration in the second half of 2018
  • 14 Oct 2016 Adverum Biotechnologies plans toxicological studies in Wet age-related macular degeneration ,
  • 14 Oct 2016 Adverum Biotechnologies plans to initiate enrolment in a phase I/II trial for Alpha-1 antitrypsin deficiency (Intravenous) (Intrapleural) (NCT02168686)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top